Changes in Kidney Function Following Heart Failure Treatment: Focus on Renin-Angiotensin System Blockade

Jessup, 2003, Heart failure, N Engl J Med, 348, 2007, 10.1056/NEJMra021498 Hunt, 2005, Circulation, 112, e154, 10.1161/CIRCULATIONAHA.105.167586 Taylor, 2004, Combination of isosorbide dinitrate and hydralazine in blacks with heart failure, N Engl J Med, 351, 2049, 10.1056/NEJMoa042934 Zisman, 1995, Angiotensin II formation in the intact human heart: predominance of the angiotensin-converting enzyme pathway, J Clin Invest, 96, 1490, 10.1172/JCI118186 Sharma, 2003, Does the kinin system mediate in cardiovascular abnormalities? An overview, J Clin Pharmacol, 43, 1187, 10.1177/0091270003258171 Garg, 1995, Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure: Collaborative Group on ACE Inhibitor Trials, JAMA, 273, 1450, 10.1001/jama.1995.03520420066040 Flather, 2000, Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group, Lancet, 355, 1575, 10.1016/S0140-6736(00)02212-1 1987, CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS): the CONSENSUS Trial Study Group, N Engl J Med, 316, 1429, 10.1056/NEJM198706043162301 1991, SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure: the SOLVD investigators, N Engl J Med, 325, 293, 10.1056/NEJM199108013250501 1992, SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions: the SOLVD investigators, N Engl J Med, 327, 685, 10.1056/NEJM199209033271003 Pfeffer, 1992, Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. The SAVE investigators, N Engl J Med, 327, 669, 10.1056/NEJM199209033271001 1993, Lancet, 342, 821 Kober, 1995, A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction: Trandolapril Cardiac Evaluation (TRACE) Study Group, N Engl J Med, 333, 1670, 10.1056/NEJM199512213332503 Jong, 2002, Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials, J Am Coll Cardiol, 39, 463, 10.1016/S0735-1097(01)01775-2 Granger, 2003, Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting enzyme inhibitors: the CHARM-Alternative trial, Lancet, 362, 772, 10.1016/S0140-6736(03)14284-5 Lee, 2004, Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction, Ann Intern Med, 141, 693, 10.7326/0003-4819-141-9-200411020-00011 Pitt, 1997, Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE), Lancet, 349, 747, 10.1016/S0140-6736(97)01187-2 Pitt, 2000, Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial–the Losartan Heart Failure Survival Study ELITE II, Lancet, 355, 1582, 10.1016/S0140-6736(00)02213-3 McKelvie, 1999, Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD pilot study investigators, Circulation, 100, 1056, 10.1161/01.CIR.100.10.1056 Cohn, 2001, A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure, N Engl J Med, 345, 1667, 10.1056/NEJMoa010713 McMurray, 2003, Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting enzyme inhibitors: the CHARM-Added trial, Lancet, 362, 767, 10.1016/S0140-6736(03)14283-3 Pfeffer, 2003, Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme, Lancet, 362, 759, 10.1016/S0140-6736(03)14282-1 Yusuf, 2003, Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial, Lancet, 362, 777, 10.1016/S0140-6736(03)14285-7 Bhakta, 2004, Angiotensin-receptor blockers in heart failure: evidence from the CHARM trial, Cleve Clin J Med, 71, 665, 10.3949/ccjm.71.8.665 Kunz, 2008, Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease, Ann Intern Med, 148, 30, 10.7326/0003-4819-148-1-200801010-00190 Phillips, 2007, Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials, Arch Intern Med, 167, 1930, 10.1001/archinte.167.18.1930 Juurlink, 2004, Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study, N Engl J Med, 351, 543, 10.1056/NEJMoa040135 Cicoira, 2002, Relation of aldosterone “escape” despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy, Am J Cardiol, 89, 403, 10.1016/S0002-9149(01)02261-5 Pitt, 1999, The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study investigators, N Engl J Med, 341, 709, 10.1056/NEJM199909023411001 Masoudi, 2004, National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction, Circulation, 110, 724, 10.1161/01.CIR.0000138934.28340.ED Echemann, 2000, Determinants of angiotensin-converting enzyme inhibitor prescription in severe heart failure with left ventricular systolic dysfunction: the EPICAL study, Am Heart J, 139, 624, 10.1016/S0002-8703(00)90039-5 de Groote, 2007, Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey, Eur J Heart Fail, 9, 1205, 10.1016/j.ejheart.2007.09.008 Lee, 2005, Risk-treatment mismatch in the pharmacotherapy of heart failure, JAMA, 294, 1240, 10.1001/jama.294.10.1240 Hillege, 2006, Renal function as a predictor of outcome in a broad spectrum of patients with heart failure, Circulation, 113, 671, 10.1161/CIRCULATIONAHA.105.580506 Lee, 1986, Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure, Circulation, 73, 257, 10.1161/01.CIR.73.2.257 Gambassi, 2000, Effects of angiotensin-converting enzyme inhibitors and digoxin on health outcomes of very old patients with heart failure: SAGE Study Group (Systematic Assessment of Geriatric drug use via Epidemiology), Arch Intern Med, 160, 53, 10.1001/archinte.160.1.53 Havranek, 1998, Determinants of mortality in elderly patients with heart failure: the role of angiotensin-converting enzyme inhibitors, Arch Intern Med, 158, 2024, 10.1001/archinte.158.18.2024 Ahmed, 2002, Survival benefits of angiotensin-converting enzyme inhibitors in older heart failure patients with perceived contraindications, J Am Geriatr Soc, 50, 1659, 10.1046/j.1532-5415.2002.50457.x Knight, 1999, Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD), Am Heart J, 138, 849, 10.1016/S0002-8703(99)70009-8 Palmer, 2003, Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what to do if the serum creatinine and/or serum potassium concentration rises, Nephrol Dial Transplant, 18, 1973, 10.1093/ndt/gfg282 Apperloo, 1997, A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function, Kidney Int, 51, 793, 10.1038/ki.1997.111 Bakris, 2000, Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?, Arch Intern Med, 160, 685, 10.1001/archinte.160.5.685 Bakris, 2000, ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group, Kidney Int, 58, 2084, 10.1111/j.1523-1755.2000.00381.x Chobanian, 2003, The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report, JAMA, 289, 2560, 10.1001/jama.289.19.2560